185 related articles for article (PubMed ID: 32336419)
1. CD123 as a Therapeutic Target Against Malignant Stem Cells.
Sugita M; Guzman ML
Hematol Oncol Clin North Am; 2020 Jun; 34(3):553-564. PubMed ID: 32336419
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Xue T; Budde LE
Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
[TBL] [Abstract][Full Text] [Related]
3. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
[TBL] [Abstract][Full Text] [Related]
4. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
[TBL] [Abstract][Full Text] [Related]
6. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Pelosi E; Castelli G; Testa U
Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
[TBL] [Abstract][Full Text] [Related]
7. CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia.
Shi M; Su RJ; Parmar KP; Chaudhry R; Sun K; Rao J; Chen M
Cardiovasc Hematol Disord Drug Targets; 2019; 19(3):195-204. PubMed ID: 31244444
[TBL] [Abstract][Full Text] [Related]
8. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
9. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
Kikushige Y; Miyamoto T
Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
[TBL] [Abstract][Full Text] [Related]
10. [Molecular targeted therapy for leukemic stem cells].
Kikushige Y
Nihon Rinsho; 2015 May; 73(5):811-5. PubMed ID: 25985636
[TBL] [Abstract][Full Text] [Related]
11. Phenotyping and Target Expression Profiling of CD34
Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
[TBL] [Abstract][Full Text] [Related]
13. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
Kikushige Y; Miyamoto T
Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
[TBL] [Abstract][Full Text] [Related]
14. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance.
Zhi L; Wang M; Rao Q; Yu F; Mi Y; Wang J
Cancer Lett; 2010 Oct; 296(1):65-73. PubMed ID: 20444543
[TBL] [Abstract][Full Text] [Related]
15. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
16. Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
Yabushita T; Satake H; Maruoka H; Morita M; Katoh D; Shimomura Y; Yoshioka S; Morimoto T; Ishikawa T
Leuk Lymphoma; 2018 Sep; 59(9):2144-2151. PubMed ID: 29251166
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
18. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
[No Abstract] [Full Text] [Related]
19. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.
Marchand T; Pinho S
Front Immunol; 2021; 12():775128. PubMed ID: 34721441
[TBL] [Abstract][Full Text] [Related]
20. ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia.
Mohd Amin A; Panneerselvan N; Md Noor S; Mohtaruddin N; Sathar J; Norbaya WS; Osman R; Kee LH; Mohd Yaakub WH; Cheong SK; Abdullah M
Malays J Pathol; 2023 Apr; 45(1):65-76. PubMed ID: 37119247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]